This IP is designed to combat neuroblastoma, a type of tumor commonly affecting children. It involves the development of an early generation oncolytic virus engineered to express a neuroblastoma antigen (Phox2B), thereby enhancing immune recognition of the tumor. This virus is intended to work synergistically with a specific engineered CAR-T cell designed to target the Phox2B-MHCI associated antigen. By harnessing the body’s immune system, the therapy aims to improve immune-mediated anti-tumor activity against neuroblastoma. One of the key advantages of this technology is its early generation ICP34.5 deletion virus backbone, which has been safely used in pediatric solid tumor clinical trials. This feature facilitates easier translation to clinical trials, particularly in pediatric settings, potentially streamlining the regulatory approval process. The potential applications of this technology are vast. As a standalone therapy, it offers a promising option for patients with neuroblastoma or tumors expressing the Phox2B antigen. When combined with engineered CAR-T therapy, it holds the potential to synergistically enhance anti-tumor activity, thus overcoming potential evasion mechanisms associated with CAR-T therapy. Further development of the IP involves pre-clinical testing in conjunction with CAR-T therapy using patient-derived xenograft models. Subsequent steps include cGMP production, IND approval, and potential clinical trials.